Maze Therapeutics (NASDAQ:MAZE) SVP Sells $73,600.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total value of $73,600.00. Following the completion of the transaction, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $381,689.60. The trade was a 16.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amy Bachrodt also recently made the following trade(s):

• On Monday, February 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $46.04, for a total value of $230,200.00.
• On Thursday, January 22nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $45.52, for a total value of $227,600.00.
• On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $39.15, for a total value of $195,750.00.

Maze Therapeutics Trading Down 1.2%

Maze Therapeutics stock traded down $0.34 on Thursday, hitting $28.71. 780,343 shares of the stock traded hands, compared to its average volume of 709,583. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $53.65. The firm has a market cap of $1.43 billion, a P/E ratio of -8.89 and a beta of 5.14. The business’s fifty day simple moving average is $44.79 and its 200 day simple moving average is $37.94.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics in the fourth quarter worth about $145,000. Invesco Ltd. grew its holdings in shares of Maze Therapeutics by 1.5% during the fourth quarter. Invesco Ltd. now owns 134,033 shares of the company’s stock valued at $5,553,000 after buying an additional 1,971 shares during the last quarter. ADAR1 Capital Management LLC increased its position in shares of Maze Therapeutics by 589.3% during the fourth quarter. ADAR1 Capital Management LLC now owns 179,532 shares of the company’s stock valued at $7,438,000 after acquiring an additional 153,487 shares in the last quarter. XTX Topco Ltd increased its position in shares of Maze Therapeutics by 22.9% during the fourth quarter. XTX Topco Ltd now owns 33,021 shares of the company’s stock valued at $1,368,000 after acquiring an additional 6,154 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in Maze Therapeutics in the 4th quarter worth approximately $2,536,000.

Wall Street Analyst Weigh In

MAZE has been the subject of a number of analyst reports. Truist Financial began coverage on shares of Maze Therapeutics in a research note on Tuesday, March 17th. They set a “buy” rating and a $68.00 target price for the company. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. HC Wainwright upped their price target on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. boosted their target price on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $66.44.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.